Page last updated: 2024-08-16

timolol and Paronychia

timolol has been researched along with Paronychia in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's3 (60.00)2.80

Authors

AuthorsStudies
Chen, CL; Chuang, CH; Liu, HL; Wei, PJ; Yang, CJ1
Azcona, M; Bernabeu-Wittel, J; Martínez-de-Espronceda, I; Monserrat, MT1
Bhullar, S; Coleman, EL; Leventhal, JS; Olamiju, B1
Cubiró, X; Garcia-Muret, MP; Planas-Ciudad, S; Puig, L1
Casassa, E; D'Andrea, M; Sibaud, V1

Other Studies

5 other study(ies) available for timolol and Paronychia

ArticleYear
Combination of available topical beta-blockers and antibiotic ointment for epidermal growth factor receptor tyrosine kinase inhibitor-induced paronychia and pseudopyogenic granulomas in Taiwan.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:6

    Topics: Aged; Angiolymphoid Hyperplasia with Eosinophilia; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Neomycin; Ointments; Ophthalmic Solutions; Paronychia; Protein Kinase Inhibitors; Retrospective Studies; Taiwan; Timolol; Tyrosine Kinase Inhibitors; Tyrothricin

2023
Recalcitrant trametinib-induced paronychia treated successfully with topical timolol in a pediatric patient.
    Dermatologic therapy, 2020, Volume: 33, Issue:1

    Topics: Administration, Topical; Adrenergic beta-Antagonists; Antineoplastic Agents; Child, Preschool; Glioma; Humans; Male; Paronychia; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Timolol; Treatment Outcome

2020
Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: An assessment of topical timolol and the need for multiple medical and procedural therapies.
    Journal of the American Academy of Dermatology, 2021, Volume: 84, Issue:3

    Topics: Administration, Topical; Adrenergic beta-Antagonists; Aged; Angiolymphoid Hyperplasia with Eosinophilia; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cryotherapy; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Protein Kinase Inhibitors; Retrospective Studies; Severity of Illness Index; Silver Nitrate; Timolol; Treatment Outcome

2021
Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine.
    JAMA dermatology, 2018, 01-01, Volume: 154, Issue:1

    Topics: Administration, Topical; Aged; Angiolymphoid Hyperplasia with Eosinophilia; Antimetabolites, Antineoplastic; Capecitabine; Cohort Studies; Female; Humans; Male; Middle Aged; Neoplasms; Paronychia; Prognosis; Retrospective Studies; Timolol; Treatment Outcome

2018
Are topical beta-blockers really effective "in real life" for targeted therapy-induced paronychia.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2019, Volume: 27, Issue:7

    Topics: Administration, Topical; Adrenergic beta-Antagonists; Humans; Paronychia; Timolol

2019